Home LiteratureArticle Details
PMID: 23535846 Published · ppublish English Research Support, Non-U.S. Gov't Review

Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance?

Nature reviews. Cancer ·Vol. 13 ·No. 5 ·2013-00-00 ·Pages 365-76

Hölzel M, Bovier A, Tüting T

Abstract

Immunotherapies, signal transduction inhibitors and chemotherapies can successfully achieve remissions in advanced stage cancer patients, but durable responses are rare. Using malignant melanoma as a paradigm, we propose that therapy-induced injury to tumour tissue and the resultant inflammation can activate protective and regenerative responses that represent a shared resistance mechanism to different treatments. Inflammation-driven phenotypic plasticity alters the antigenic landscape of tumour cells, rewires oncogenic signalling networks, protects against cell death and reprogrammes immune cell functions. We propose that the successful combination of cancer treatments to tackle resistance requires an interdisciplinary understanding of these resistance mechanisms, supported by mathematical models.

MeSH Terms
Animals Drug Resistance, Neoplasm Humans Immune System/pathology Immunotherapy Inflammation Melanoma/immunology,pathology,therapy Models, Biological Molecular Targeted Therapy Neoplasm Recurrence, Local Neoplastic Stem Cells/immunology,metabolism Tumor Microenvironment
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Hölzel Michael
Unit for RNA Biology, Department of Clinical Chemistry and Clinical Pharmacology, University of Bonn, 53105 Bonn, Germany.
Bovier Anton
Tüting Thomas
References (169)
169 references, click to expand
  1. Accessories to the crime: functions of cells recruited to the tumor microenvironment.
    Cancer Cell. 2012 Mar 20;21(3):309-22 PMID: 22439926
  2. Tumors as organs: complex tissues that interface with the entire organism.
    Dev Cell. 2010 Jun 15;18(6):884-901 PMID: 20627072
  3. Functional roles for noise in genetic circuits.
    Nature. 2010 Sep 9;467(7312):167-73 PMID: 20829787
  4. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion.
    Science. 2011 Mar 25;331(6024):1565-70 PMID: 21436444
  5. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993.
    J Clin Oncol. 1999 Jul;17(7):2105-16 PMID: 10561265
  6. Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance.
    Cancer Cell. 2012 Apr 17;21(4):488-503 PMID: 22516258
  7. DNA damage-mediated induction of a chemoresistant niche.
    Cell. 2010 Oct 29;143(3):355-66 PMID: 21029859
  8. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.
    Science. 2001 Aug 3;293(5531):876-80 PMID: 11423618
  9. Natural selection of tumor variants in the generation of "tumor escape" phenotypes.
    Nat Immunol. 2002 Nov;3(11):999-1005 PMID: 12407407
  10. Management of cutaneous melanoma.
    N Engl J Med. 2004 Sep 2;351(10):998-1012 PMID: 15342808
  11. Cancer drug pan-resistance: pumps, cancer stem cells, quiescence, epithelial to mesenchymal transition, blocked cell death pathways, persisters or what?
    Open Biol. 2012 May;2(5):120066 PMID: 22724067
  12. T cell exhaustion.
    Nat Immunol. 2011 Jun;12(6):492-9 PMID: 21739672
  13. Growth interaction in vivo between tumor subpopulations derived from a single mouse mammary tumor.
    Cancer Res. 1980 Nov;40(11):3977-81 PMID: 7471048
  14. Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotype.
    Proc Natl Acad Sci U S A. 2012 Mar 20;109(12):4592-7 PMID: 22393002
  15. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes.
    Science. 2002 Oct 25;298(5594):850-4 PMID: 12242449
  16. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.
    J Clin Oncol. 2005 Apr 1;23(10):2346-57 PMID: 15800326
  17. A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment.
    Cancer Res. 2012 Jan 1;72(1):66-75 PMID: 22065722
  18. Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines.
    Cancer Res. 2006 Jan 15;66(2):944-50 PMID: 16424029
  19. "Hard" and "soft" lesions underlying the HLA class I alterations in cancer cells: implications for immunotherapy.
    Int J Cancer. 2010 Jul 15;127(2):249-56 PMID: 20178101
  20. Improved survival with MEK inhibition in BRAF-mutated melanoma.
    N Engl J Med. 2012 Jul 12;367(2):107-14 PMID: 22663011
  21. Cancer immunotherapy: moving beyond current vaccines.
    Nat Med. 2004 Sep;10(9):909-15 PMID: 15340416
  22. Cancer as an evolutionary and ecological process.
    Nat Rev Cancer. 2006 Dec;6(12):924-35 PMID: 17109012
  23. Scatter factor/hepatocyte growth factor as a regulator of skeletal muscle and neural crest development.
    Proc Natl Acad Sci U S A. 1996 Jun 11;93(12):5866-71 PMID: 8650184
  24. Downregulation of E-cadherin and Desmoglein 1 by autocrine hepatocyte growth factor during melanoma development.
    Oncogene. 2001 Dec 6;20(56):8125-35 PMID: 11781826
  25. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.
    N Engl J Med. 2012 Jun 28;366(26):2455-65 PMID: 22658128
  26. Macrophage diversity enhances tumor progression and metastasis.
    Cell. 2010 Apr 2;141(1):39-51 PMID: 20371344
  27. Hallmarks of cancer: the next generation.
    Cell. 2011 Mar 4;144(5):646-74 PMID: 21376230
  28. Resistance, epigenetics and the cancer ecosystem.
    Nat Med. 2011 Mar;17(3):288-9 PMID: 21383739
  29. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion.
    Nature. 2012 Jul 26;487(7408):500-4 PMID: 22763439
  30. Identification of multiple antigens recognized by tumor-infiltrating lymphocytes from a single patient: tumor escape by antigen loss and loss of MHC expression.
    J Immunother. 2004 May-Jun;27(3):184-90 PMID: 15076135
  31. Molecular plasticity of human melanoma cells.
    Oncogene. 2003 May 19;22(20):3070-5 PMID: 12789282
  32. Improved survival with ipilimumab in patients with metastatic melanoma.
    N Engl J Med. 2010 Aug 19;363(8):711-23 PMID: 20525992
  33. Chemotherapeutic resistance: surviving stressful situations.
    Cancer Res. 2011 Aug 1;71(15):5062-6 PMID: 21771909
  34. Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer.
    Science. 2013 Feb 1;339(6119):543-8 PMID: 23239622
  35. TGFbeta/TNF(alpha)-mediated epithelial-mesenchymal transition generates breast cancer stem cells with a claudin-low phenotype.
    Cancer Res. 2011 Jul 1;71(13):4707-19 PMID: 21555371
  36. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations.
    Cell. 2010 Apr 2;141(1):69-80 PMID: 20371346
  37. Metabolic tumor imaging using magnetic resonance spectroscopy.
    Semin Oncol. 2011 Feb;38(1):26-41 PMID: 21362514
  38. A fully automated two-step synthesis of an (18)F-labelled tyrosine kinase inhibitor for EGFR kinase activity imaging in tumors.
    Appl Radiat Isot. 2009 Nov;67(11):1977-84 PMID: 19695886
  39. TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer.
    Proc Natl Acad Sci U S A. 2010 Aug 31;107(35):15535-40 PMID: 20713723
  40. Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation.
    Nature. 2012 Oct 18;490(7420):412-6 PMID: 23051752
  41. Systematic classification of melanoma cells by phenotype-specific gene expression mapping.
    Pigment Cell Melanoma Res. 2012 May;25(3):343-53 PMID: 22336146
  42. Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia.
    Science. 2008 Nov 28;322(5906):1377-80 PMID: 19039135
  43. PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines.
    Cancer Res. 2012 Oct 15;72(20):5209-18 PMID: 22915761
  44. Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations.
    Clin Cancer Res. 2011 Mar 1;17(5):1160-8 PMID: 21233402
  45. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape.
    Sci Transl Med. 2012 Mar 28;4(127):127ra37 PMID: 22461641
  46. Adoptive immunotherapy for cancer: harnessing the T cell response.
    Nat Rev Immunol. 2012 Mar 22;12(4):269-81 PMID: 22437939
  47. Genetic variegation of clonal architecture and propagating cells in leukaemia.
    Nature. 2011 Jan 20;469(7330):356-61 PMID: 21160474
  48. Chromosomal instability and cancer: a complex relationship with therapeutic potential.
    J Clin Invest. 2012 Apr;122(4):1138-43 PMID: 22466654
  49. Epithelial to mesenchymal transition is a determinant of sensitivity to chemoradiotherapy in non-small cell lung cancer.
    Ann Thorac Surg. 2011 Nov;92(5):1794-804; discussion 1804 PMID: 22051275
  50. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.
    N Engl J Med. 2012 Mar 8;366(10):883-892 PMID: 22397650
  51. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.
    Nature. 2010 Dec 16;468(7326):973-7 PMID: 21107323
  52. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
    N Engl J Med. 2012 Jun 28;366(26):2443-54 PMID: 22658127
  53. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.
    N Engl J Med. 2010 Jun 24;362(25):2380-8 PMID: 20573926
  54. Cancer immunotherapy: a treatment for the masses.
    Science. 2004 Jul 9;305(5681):200-5 PMID: 15247469
  55. Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model.
    Proc Natl Acad Sci U S A. 2011 Oct 11;108(41):17111-6 PMID: 21969559
  56. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.
    Nature. 2012 Jan 26;483(7387):100-3 PMID: 22281684
  57. In vivo switching of human melanoma cells between proliferative and invasive states.
    Cancer Res. 2008 Feb 1;68(3):650-6 PMID: 18245463
  58. Melanoma revives an embryonic migration program to promote plasticity and invasion.
    Pigment Cell Melanoma Res. 2012 Sep;25(5):573-83 PMID: 22681858
  59. Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma.
    J Immunol. 2010 Apr 1;184(7):3442-9 PMID: 20194714
  60. Evolution of cooperation among tumor cells.
    Proc Natl Acad Sci U S A. 2006 Sep 5;103(36):13474-9 PMID: 16938860
  61. Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort.
    J Thorac Oncol. 2011 Dec;6(12):2011-7 PMID: 22052230
  62. Multidrug resistance in cancer: role of ATP-dependent transporters.
    Nat Rev Cancer. 2002 Jan;2(1):48-58 PMID: 11902585
  63. Exhaustion of tumor-specific CD8⁺ T cells in metastases from melanoma patients.
    J Clin Invest. 2011 Jun;121(6):2350-60 PMID: 21555851
  64. Long-term single-cell imaging of mammalian stem cells.
    Nat Methods. 2011 Apr;8(4 Suppl):S30-5 PMID: 21451514
  65. Immunosuppressive networks in the tumour environment and their therapeutic relevance.
    Nat Rev Cancer. 2005 Apr;5(4):263-74 PMID: 15776005
  66. Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
    N Engl J Med. 2011 Jun 30;364(26):2507-16 PMID: 21639808
  67. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy.
    Cancer Discov. 2011 Jun;1(1):54-67 PMID: 22039576
  68. Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies.
    Cell. 2012 Jan 20;148(1-2):362-75 PMID: 22265421
  69. The cancer stem cell: premises, promises and challenges.
    Nat Med. 2011 Mar;17(3):313-9 PMID: 21386835
  70. New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site.
    J Immunol. 2006 Aug 1;177(3):1670-8 PMID: 16849476
  71. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features.
    Proc Natl Acad Sci U S A. 2009 Aug 18;106(33):13820-5 PMID: 19666588
  72. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells.
    Nature. 2011 Jul 13;475(7355):226-30 PMID: 21753853
  73. The parallel lives of angiogenesis and immunosuppression: cancer and other tales.
    Nat Rev Immunol. 2011 Sep 23;11(10):702-11 PMID: 21941296
  74. The therapeutic promise of the cancer stem cell concept.
    J Clin Invest. 2010 Jan;120(1):41-50 PMID: 20051635
  75. Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks.
    Cell. 2012 May 11;149(4):780-94 PMID: 22579283
  76. Melanoma: from mutations to medicine.
    Genes Dev. 2012 Jun 1;26(11):1131-55 PMID: 22661227
  77. Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth.
    Nat Med. 2013 Jan;19(1):57-64 PMID: 23202296
  78. Human T cell responses against melanoma.
    Annu Rev Immunol. 2006;24:175-208 PMID: 16551247
  79. Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271.
    Nature. 2010 Jul 1;466(7302):133-7 PMID: 20596026
  80. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability.
    Carcinogenesis. 2009 Jul;30(7):1073-81 PMID: 19468060
  81. Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer.
    Genes Dev. 2011 Dec 1;25(23):2465-79 PMID: 22156207
  82. Tumor-initiated inflammation overrides protective adaptive immunity in an induced melanoma model in mice.
    Cancer Res. 2010 May 1;70(9):3515-25 PMID: 20406967
  83. Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells.
    Nature. 2011 Jan 20;469(7330):362-7 PMID: 21248843
  84. Transcriptome-wide noise controls lineage choice in mammalian progenitor cells.
    Nature. 2008 May 22;453(7194):544-7 PMID: 18497826
  85. Gatekeeper mutations mediate resistance to BRAF-targeted therapies.
    Sci Transl Med. 2010 Jun 9;2(35):35ra41 PMID: 20538618
  86. Systemic cancer progression and tumor dormancy: mathematical models meet single cell genomics.
    Cell Cycle. 2006 Aug;5(16):1788-98 PMID: 16929175
  87. Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized.
    Cancer Cell. 2010 Nov 16;18(5):510-23 PMID: 21075313
  88. The therapeutic implications of plasticity of the cancer stem cell phenotype.
    PLoS One. 2010 Dec 17;5(12):e14366 PMID: 21179426
  89. Mesenchymal transition and dissemination of cancer cells is driven by myeloid-derived suppressor cells infiltrating the primary tumor.
    PLoS Biol. 2011 Sep;9(9):e1001162 PMID: 21980263
  90. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells.
    Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16168-73 PMID: 12427970
  91. Complete regression of advanced primary and metastatic mouse melanomas following combination chemoimmunotherapy.
    Cancer Res. 2009 Aug 1;69(15):6265-74 PMID: 19622767
  92. Timeline: Chemotherapy and the war on cancer.
    Nat Rev Cancer. 2005 Jan;5(1):65-72 PMID: 15630416
  93. Mutant BRAF melanomas--dependence and resistance.
    Cancer Cell. 2011 Jan 18;19(1):11-5 PMID: 21251612
  94. Intravital imaging reveals transient changes in pigment production and Brn2 expression during metastatic melanoma dissemination.
    Cancer Res. 2009 Oct 15;69(20):7969-77 PMID: 19826052
  95. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.
    N Engl J Med. 2005 Feb 24;352(8):786-92 PMID: 15728811
  96. Transcriptional and epigenetic control of T helper cell specification: molecular mechanisms underlying commitment and plasticity.
    Annu Rev Immunol. 2012;30:707-31 PMID: 22224760
  97. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet.
    Blood. 2011 Aug 4;118(5):1208-15 PMID: 21562040
  98. A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth.
    Cell. 2010 May 14;141(4):583-94 PMID: 20478252
  99. Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance.
    Drug Resist Updat. 2012 Feb-Apr;15(1-2):21-38 PMID: 22356866
  100. Immunoediting of cancers may lead to epithelial to mesenchymal transition.
    J Immunol. 2006 Aug 1;177(3):1526-33 PMID: 16849459
  101. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.
    Nature. 2010 Dec 16;468(7326):968-72 PMID: 21107320
  102. Autochthonous primary and metastatic melanomas in Hgf-Cdk4 R24C mice evade T-cell-mediated immune surveillance.
    Pigment Cell Melanoma Res. 2010 Oct;23(5):649-60 PMID: 20649939
  103. Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor.
    Oncogene. 2010 Apr 22;29(16):2346-56 PMID: 20118985
  104. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
    Science. 2004 Jun 4;304(5676):1497-500 PMID: 15118125
  105. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer.
    Nat Genet. 2012 Jul 01;44(8):852-60 PMID: 22751098
  106. Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer.
    J Clin Oncol. 2012 Feb 1;30(4):433-40 PMID: 22215752
  107. A functional role for tumor cell heterogeneity in a mouse model of small cell lung cancer.
    Cancer Cell. 2011 Feb 15;19(2):244-56 PMID: 21316603
  108. Modulation of microenvironment acidity reverses anergy in human and murine tumor-infiltrating T lymphocytes.
    Cancer Res. 2012 Jun 1;72(11):2746-56 PMID: 22593198
  109. Cluster analysis and display of genome-wide expression patterns.
    Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 PMID: 9843981
  110. Cancer stem cells: impact, heterogeneity, and uncertainty.
    Cancer Cell. 2012 Mar 20;21(3):283-96 PMID: 22439924
  111. Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia.
    Cancer Cell. 2012 Jun 12;21(6):836-47 PMID: 22698407
  112. Human CD271-positive melanoma stem cells associated with metastasis establish tumor heterogeneity and long-term growth.
    Cancer Res. 2011 Apr 15;71(8):3098-109 PMID: 21393506
  113. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis.
    Nature. 2011 Jun 08;475(7355):222-5 PMID: 21654748
  114. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer.
    Oncogene. 2010 Aug 26;29(34):4741-51 PMID: 20531305
  115. A spatially-organized multicellular innate immune response in lymph nodes limits systemic pathogen spread.
    Cell. 2012 Sep 14;150(6):1235-48 PMID: 22980983
  116. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma.
    Nature. 2010 Sep 30;467(7315):596-9 PMID: 20823850
  117. Immunosuppressive strategies that are mediated by tumor cells.
    Annu Rev Immunol. 2007;25:267-96 PMID: 17134371
  118. Environment-mediated drug resistance: a major contributor to minimal residual disease.
    Nat Rev Cancer. 2009 Sep;9(9):665-74 PMID: 19693095
  119. Melanocytes in development, regeneration, and cancer.
    Cell Stem Cell. 2008 Sep 11;3(3):242-52 PMID: 18786412
  120. How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine.
    Br J Cancer. 2010 Oct 12;103(8):1139-43 PMID: 20877357
  121. Cancer immunotherapy comes of age.
    Nature. 2011 Dec 21;480(7378):480-9 PMID: 22193102
  122. Tumor necrosis factor-alpha blocks apoptosis in melanoma cells when BRAF signaling is inhibited.
    Cancer Res. 2007 Jan 1;67(1):122-9 PMID: 17210691
  123. Interferon-γ links ultraviolet radiation to melanomagenesis in mice.
    Nature. 2011 Jan 27;469(7331):548-53 PMID: 21248750
  124. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells.
    Nat Med. 1996 May;2(5):561-6 PMID: 8616716
  125. The cadherin switch in melanoma instigated by HGF is mediated through epithelial-mesenchymal transition regulators.
    Pigment Cell Melanoma Res. 2011 Apr;24(2):382-5 PMID: 21091638
  126. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance.
    Clin Cancer Res. 2013 Jan 1;19(1):279-90 PMID: 23091115
  127. Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma.
    Int J Cancer. 1997 Apr 10;71(2):142-7 PMID: 9139833
  128. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance.
    Nature. 2013 Feb 14;494(7436):251-5 PMID: 23302800
  129. Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells.
    Cell. 2011 Aug 19;146(4):633-44 PMID: 21854987
  130. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.
    N Engl J Med. 2011 Jun 30;364(26):2517-26 PMID: 21639810
  131. Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice.
    J Clin Invest. 2010 Mar;120(3):694-705 PMID: 20179352
  132. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.
    Sci Transl Med. 2011 Mar 23;3(75):75ra26 PMID: 21430269
  133. Progress in human tumour immunology and immunotherapy.
    Nature. 2001 May 17;411(6835):380-4 PMID: 11357146
  134. MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling.
    Cell. 2012 Nov 21;151(5):937-50 PMID: 23178117
  135. Macrophage plasticity and polarization: in vivo veritas.
    J Clin Invest. 2012 Mar;122(3):787-95 PMID: 22378047
  136. Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma.
    J Clin Oncol. 2006 Nov 1;24(31):5060-9 PMID: 17075125
  137. Pushing the limits of targeted therapy in chronic myeloid leukaemia.
    Nat Rev Cancer. 2012 Jul 24;12(8):513-26 PMID: 22825216
  138. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib.
    Cancer Discov. 2012 Mar;2(3):227-35 PMID: 22448344
  139. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.
    Nature. 2012 Jul 26;487(7408):505-9 PMID: 22763448
  140. Dormancy of metastatic melanoma.
    Pigment Cell Melanoma Res. 2010 Feb;23(1):41-56 PMID: 19843243
  141. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K.
    Cancer Cell. 2010 Dec 14;18(6):683-95 PMID: 21156289
  142. The tumor microenvironment is a dominant force in multidrug resistance.
    Drug Resist Updat. 2012 Feb-Apr;15(1-2):39-49 PMID: 22335920
  143. A CXCL1 paracrine network links cancer chemoresistance and metastasis.
    Cell. 2012 Jul 6;150(1):165-78 PMID: 22770218
  144. Tumour-initiating cells: challenges and opportunities for anticancer drug discovery.
    Nat Rev Drug Discov. 2009 Oct;8(10):806-23 PMID: 19794444
  145. Evolutionary dynamics of carcinogenesis and why targeted therapy does not work.
    Nat Rev Cancer. 2012 Jun 14;12(7):487-93 PMID: 22695393
  146. Imaging molecular pathways: reporter genes.
    Radiat Res. 2012 Apr;177(4):508-13 PMID: 22348248
  147. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
    N Engl J Med. 2004 May 20;350(21):2129-39 PMID: 15118073
  148. Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma.
    J Immunol. 2005 Nov 1;175(9):6169-76 PMID: 16237114
  149. Accumulation of driver and passenger mutations during tumor progression.
    Proc Natl Acad Sci U S A. 2010 Oct 26;107(43):18545-50 PMID: 20876136
  150. Intestinal tumorigenesis initiated by dedifferentiation and acquisition of stem-cell-like properties.
    Cell. 2013 Jan 17;152(1-2):25-38 PMID: 23273993
  151. Creating immune privilege: active local suppression that benefits friends, but protects foes.
    Nat Rev Immunol. 2008 Jan;8(1):74-80 PMID: 18064049
  152. Expression of selected gene for acquired drug resistance to EGFR-TKI in lung adenocarcinoma.
    Lung Cancer. 2011 Sep;73(3):361-5 PMID: 21315472
  153. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
    N Engl J Med. 2001 Apr 5;344(14):1031-7 PMID: 11287972
  154. Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients.
    Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):3089-94 PMID: 14970324
  155. Crosstalk to stromal fibroblasts induces resistance of lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors.
    Clin Cancer Res. 2009 Nov 1;15(21):6630-8 PMID: 19843665
  156. Stochastic switching as a survival strategy in fluctuating environments.
    Nat Genet. 2008 Apr;40(4):471-5 PMID: 18362885
  157. Mitf is the key molecular switch between mouse or human melanoma initiating cells and their differentiated progeny.
    Oncogene. 2011 May 19;30(20):2307-18 PMID: 21278797
  158. Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells.
    Cancer Res. 2009 Apr 1;69(7):2887-95 PMID: 19276366
  159. A race between tumor immunoescape and genome maintenance selects for optimum levels of (epi)genetic instability.
    PLoS Comput Biol. 2012;8(2):e1002370 PMID: 22359489
  160. Intra-tumour heterogeneity: a looking glass for cancer?
    Nat Rev Cancer. 2012 Apr 19;12(5):323-34 PMID: 22513401
  161. Cancer stem cells versus phenotype-switching in melanoma.
    Pigment Cell Melanoma Res. 2010 Dec;23(6):746-59 PMID: 20726948
  162. Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy.
    J Natl Cancer Inst. 1996 Jan 17;88(2):100-8 PMID: 8537970
  163. Neuropilin 1 deficiency on CD4+Foxp3+ regulatory T cells impairs mouse melanoma growth.
    J Exp Med. 2012 Oct 22;209(11):2001-16 PMID: 23045606
  164. Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor.
    Proc Natl Acad Sci U S A. 1997 Jan 21;94(2):701-6 PMID: 9012848
  165. Cancer attractors: a systems view of tumors from a gene network dynamics and developmental perspective.
    Semin Cell Dev Biol. 2009 Sep;20(7):869-76 PMID: 19595782
  166. GLI2 and M-MITF transcription factors control exclusive gene expression programs and inversely regulate invasion in human melanoma cells.
    Pigment Cell Melanoma Res. 2011 Oct;24(5):932-43 PMID: 21801332
  167. Using Moment Equations to Understand Stochastically Driven Spatial Pattern Formation in Ecological Systems
    Theor Popul Biol. 1997 Dec;52(3):179-97 PMID: 9466960
  168. Clonal evolution in cancer.
    Nature. 2012 Jan 18;481(7381):306-13 PMID: 22258609
  169. A multi-cancer mesenchymal transition gene expression signature is associated with prolonged time to recurrence in glioblastoma.
    PLoS One. 2012;7(4):e34705 PMID: 22493711
Article Info
Journal
Nature reviews. Cancer
Abbr.
Nat Rev Cancer
ISSN
1474-1768
DOI
10.1038/nrc3498
Published
2013-00-00
Epub
2013-00-28
Pages
365-76
Language
English
Region
England
NLM ID
101124168
Subset
IM
External Links
PubMed source DOI: 10.1038/nrc3498 View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2